Oventus reapplies to PDAC
By HME News Staff
Updated 9:12 AM CDT, Tue October 26, 2021
BRISBANE, Australia – Oventus Medical has reapplied to Palmetto GBA, the pricing data analysis and coding contractor (PDAC), for approval of the newly submitted Optima version of its O2Vent oral appliance to treat obstructive sleep apnea. This version of the device is designed specifically for Medicare patients. “In the meantime, this means that O2Vent Optima will not be able to be supplied to Medicare patients in its own right for reimbursement purposes,” the company stated. The PDAC recently recoded the previously approved O2Vent Optima as A9270, a non-covered item or service. Oventus says that, to date, Medicare patients have represented a very small percentage of its sales in the United States.
Comments